Literature DB >> 23258787

Pathways associated with reduced quadriceps oxidative fibres and endurance in COPD.

Samantha A Natanek1, Harry R Gosker, Ilse G M Slot, Gemma S Marsh, Nicholas S Hopkinson, John Moxham, Paul R Kemp, Annemie M W J Schols, Michael I Polkey.   

Abstract

Reduced quadriceps endurance in chronic obstructive pulmonary disease (COPD) is associated with a predominance of type II glycolytic fibres over type I oxidative fibres (fibre shift) and reduced muscle energy stores. The molecular mechanisms responsible for this remain unknown. We hypothesised that expression of known regulators of type I fibres and energy production in quadriceps muscle would differ in COPD patients with and without fibre shift. We measured lung function, physical activity, exercise performance, quadriceps strength and endurance (nonvolitionally) in 38 Global Initiative for Chronic Obstructive Lung Disease stage I-IV COPD patients and 23 healthy age-matched controls. Participants underwent a quadriceps biopsy: type I and II fibre proportions were determined using immunohistochemistry and fibre shift defined using published reference ranges. Calcineurin A, phosphorylated AMP kinase (phospho-AMPK)-α, protein kinase A-α catalytic subunits, modulators of calcineurin activity and calmodulin, 14-3-3 proteins were measured by Western blotting, and myocyte-enriched calcineurin-interacting protein-1 mRNA measured by quantitative PCR. Downstream, nuclear myocyte enhancer factor-2 capable of DNA binding was quantified by transcription factor ELISA. Unexpectedly, calcineurin expression was higher, while phospho-AMPK was lower, in COPD patients with fibre shift compared to COPD patients without fibre shift. Phospho-AMPK levels correlated with quadriceps endurance in patients. Reduced phospho-AMPK may contribute to reduced quadriceps oxidative capacity and endurance in COPD.

Entities:  

Keywords:  AMP kinase; calcineurin; myocyte enhancer factor-2; protein kinase A

Mesh:

Substances:

Year:  2012        PMID: 23258787     DOI: 10.1183/09031936.00098412

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 2.  Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings.

Authors:  Joaquim Gea; Sergi Pascual; Carme Casadevall; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

3.  Down-Regulation of Soluble α-Klotho is Associated with Reduction in Serum Irisin Levels in Chronic Obstructive Pulmonary Disease.

Authors:  Yuko Kureya; Hiroshi Kanazawa; Naoki Ijiri; Yoshihiro Tochino; Tetsuya Watanabe; Kazuhisa Asai; Kazuto Hirata
Journal:  Lung       Date:  2016-05-02       Impact factor: 2.584

4.  Failed upregulation of TFAM protein and mitochondrial DNA in oxidatively deficient fibers of chronic obstructive pulmonary disease locomotor muscle.

Authors:  Yana Konokhova; Sally Spendiff; R Thomas Jagoe; Sudhakar Aare; Sophia Kapchinsky; Norah J MacMillan; Paul Rozakis; Martin Picard; Mylène Aubertin-Leheudre; Charlotte H Pion; Jean Bourbeau; Russell T Hepple; Tanja Taivassalo
Journal:  Skelet Muscle       Date:  2016-02-18       Impact factor: 4.912

5.  Myocyte enhancer factor 2D provides a cross-talk between chronic inflammation and lung cancer.

Authors:  Hai-Xing Zhu; Lin Shi; Yong Zhang; Yi-Chun Zhu; Chun-Xue Bai; Xiang-Dong Wang; Jie-Bai Zhou
Journal:  J Transl Med       Date:  2017-03-24       Impact factor: 5.531

Review 6.  Resveratrol for patients with chronic obstructive pulmonary disease: hype or hope?

Authors:  Rosanne J H C G Beijers; Harry R Gosker; Annemie M W J Schols
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2018-03       Impact factor: 4.294

Review 7.  An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease.

Authors:  Nan Ran; Zhiqiang Pang; Yinuo Gu; He Pan; Xu Zuo; Xuewa Guan; Yuze Yuan; Ziyan Wang; Yingqiao Guo; Zixu Cui; Fang Wang
Journal:  Metabolites       Date:  2019-06-10

8.  Skeletal muscle adiposity is associated with physical activity, exercise capacity and fibre shift in COPD.

Authors:  Matthew Maddocks; Dinesh Shrikrishna; Simone Vitoriano; Samantha A Natanek; Rebecca J Tanner; Nicholas Hart; Paul R Kemp; John Moxham; Michael I Polkey; Nicholas S Hopkinson
Journal:  Eur Respir J       Date:  2014-07-03       Impact factor: 16.671

9.  Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo.

Authors:  Mehul S Patel; Jen Lee; Manuel Baz; Claire E Wells; Susannah Bloch; Amy Lewis; Anna V Donaldson; Benjamin E Garfield; Nicholas S Hopkinson; Amanda Natanek; William D-C Man; Dominic J Wells; Emma H Baker; Michael I Polkey; Paul R Kemp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-12-29       Impact factor: 12.910

Review 10.  Skeletal Muscle Fiber Type in Hypoxia: Adaptation to High-Altitude Exposure and Under Conditions of Pathological Hypoxia.

Authors:  Thomas Chaillou
Journal:  Front Physiol       Date:  2018-10-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.